Skip to main content
Indian Journal of Psychiatry logoLink to Indian Journal of Psychiatry
. 2000 Jul-Sep;42(3):295–301.

A DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE ANXIOLYTIC EFFICACY FF AN ETHANOLIC EXTRACT OF WITHANIA SOMNIFERA

Chittaranjan Andrade *,*, Anitha Aswath , SK Chaturvedi , M Srinivasa §, R Raguram
PMCID: PMC2958355  PMID: 21407960

Abstract

A double-blind, placebo-controlled study was conducted to evaluate the efficacy an ethanolic extract of Aswagandha (Withania somnifera), in patients with ICD-10 anxiety disorders. The sample comprised 39 subjects, of whom 20 received the drug and 19 received placebo. The two groups were sociodemographically and clinically similar at baseline. At 2 and 6 weeks follow-up, data from approximately 85% of patients in each group were available for analysis. Statistical trends favouring the drug were observed at both time points. At 6 weeks, significantly more patients met a priori response criteria in the drug group (88.2%) as compared with the placebo group (50%). The drug was well-tolerated and did not occasion more adverse effects than did placebo. It is concluded that this ethanolic extract of Withania somnifera has useful anxiolytic potential and merits further investigation.

Keywords: Anxiety disorder, generalized anxiety disorder, adjustment disorder with anxiety, panic disorder, Aswagandha, Ayurvedic treatment, herbal therapy, clinical trial

Full Text

The Full Text of this article is available as a PDF (297.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bech P., Kastrup M., Rafaelsen O. J. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl. 1986;326:1–37. [PubMed] [Google Scholar]
  2. Kessler R. C., McGonagle K. A., Zhao S., Nelson C. B., Hughes M., Eshleman S., Wittchen H. U., Kendler K. S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8–19. doi: 10.1001/archpsyc.1994.03950010008002. [DOI] [PubMed] [Google Scholar]
  3. Londborg P. D., Wolkow R., Smith W. T., DuBoff E., England D., Ferguson J., Rosenthal M., Weise C. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998 Jul;173:54–60. doi: 10.1192/bjp.173.1.54. [DOI] [PubMed] [Google Scholar]
  4. Mehta A. K., Binkley P., Gandhi S. S., Ticku M. K. Pharmacological effects of Withania somnifera root extract on GABAA receptor complex. Indian J Med Res. 1991 Aug;94:312–315. [PubMed] [Google Scholar]
  5. Schweizer E., Patterson W., Rickels K., Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry. 1993 Aug;150(8):1210–1215. doi: 10.1176/ajp.150.8.1210. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES